CPHPC Struktur

CPHPC

Bezeichnung:CPHPC

CAS-Nr224624-80-0

Englisch Name:CPHPC

CBNumberCB63147209

SummenformelC16H24N2O6

Molgewicht340.37

MOL-Datei224624-80-0.mol

CPHPC physikalisch-chemischer Eigenschaften

storage temp.	2-8°C
Löslichkeit	≤30mg/ml in ethanol;20mg/ml in DMSO;25mg/ml in dimethyl formamide
Aggregatzustand	crystalline solid
Farbe	White to off-white

Sicherheit

HS Code

2933998090

Gefahreninformationscode (GHS)

CPHPC Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Serum amyloid P (SAP) is pentraxin with roles in inflammation and immune response. CPHPC is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance. It also produces significant reduction of SAP from cerebrospinal fluid and visceral amyloid deposits. CPHPC has been used with anti-SAP antibodies to eliminate amyloid deposits in clinical trials of systemic amyloidosis.
Verwenden
Miridesap is a potential drug in the treatment of amyloidosis.
in vitro
previous study found that the multi-point binding of cphpc between pairs of pentameric sap molecules increased the avidity of the interaction, and this was reflected in an apparent affinity constant of 10 nm. moreover, the x-ray crystal structure of the sap–cphpc complex confirmed that it was a decamer composed of two pentameric sap molecules reversibly crosslinked by five cphpc molecules [1].
in vivo
mice were received cphpc at 1 mg/ml in their drinking water for the rest of the experiment. circulating human sap was depleted but significant amounts of sap remained in the amyloid deposits. five days after starting on cphpc, one group received a single intraperitoneal injection of 50 mg of the igg fraction of sheep anti-human sap antiserum, containing 7 mg of anti-sap antibody. a control group received 50 mg of unrelated sheep igg. the third group received no treatment and thus controlled for spontaneous regression of aa amyloid. results showed that there was dramatically less amyloid after treatment with cphpc plus anti-sap antibody than in the other two groups but there was no difference between cphpc alone and no treatment [2].
Einzelnachweise
[1] m. b. pepys, j. herbert, w. l. hutchinson, et al. targeted pharmacological depletion of serum amyloid p component for treatment of human amyloidosis. nature 417, 254-259 (2002).
[2] k. bodin, s. ellmerich, m. c. kahan, et al. antibodies to human serum amyloid p component eliminate visceral amyloid deposits. nature 468, 93-97 (2010).
[3] gillmore jd et al. ustained pharmacological depletion of serum amyloid p component in patients with systemic amyloidosis. br j haematol. 2010 mar;148(5):760-7.

CPHPC Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy